
Paolo Tarantino/X
Apr 12, 2025, 12:45
Paolo Tarantino: Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, posted on X:
“Results from OptiTROP-B01 out in Nature Medicine.
The TROP2-ADC sacituzumab tirumotecan improved PFS and OS in highly pretreated mTNBC, irrespective of Trop2 exp. Results similar to ASCENT. Approved in China, may soon also reach the west (4th topo1 ADC).”
“Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial.”
Authors: Yongmei Yin, Ying Fan, Quchang Ouyang, Lihua Song, Xiaojia Wang, Wei Li, Man Li, Xi Yan, Shusen Wang, Tao Sun, Yuee Teng, Xianjun Tang, Zhongsheng Tong, Zhengkui Sun, Junyou Ge, Xiaoping Jin, Yina Diao, Gesha Liu, Binghe Xu
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 10:23
Apr 15, 2025, 10:22
Apr 15, 2025, 10:17
Apr 15, 2025, 10:09
Apr 15, 2025, 10:04
Apr 15, 2025, 09:54
Apr 15, 2025, 09:48
Apr 15, 2025, 09:45
Apr 15, 2025, 09:37
Apr 15, 2025, 09:34
Apr 15, 2025, 09:30